treatment protocol

OTHER5 trials

Sponsors

National Hospital Organization Disaster Medical Center, Medical University of Vienna, Canadian Scleroderma Research Group, University of Alcala, The Second Hospital of Shandong University

Conditions

AdenomyosisLymphoma, Mantle-CellSmall Intestinal Bacterial OvergrowthStrokeSystemic Sclerosisin Vitro Fertilizationmultiple myeloma

Phase 2

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Medical University of ViennaLymphoma, Mantle-Cell

Start: 2005-01-31End: 2007-01-31Target: 16Updated: 2006-10-18

The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients.

RecruitingJPRN-UMIN000007803

National Hospital Organization Disaster Medical Centermultiple myeloma

Start: 2011-08-01Target: 35Updated: 2026-06-29

Unknown Phase

The Small Intestine Bacterial Overgrowth Study Pilot

Canadian Scleroderma Research GroupSmall Intestinal Bacterial Overgrowth, Systemic Sclerosis

Start: 2019-02-15End: 2021-09-01Target: 500Updated: 2019-10-17

Effectiveness of Physiotherapy After Stroke

Active, not recruitingNCT06165666

University of AlcalaStroke

Start: 2024-02-12End: 2026-10-31Updated: 2024-05-31

Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart)

Active, not recruitingNCT06604091

The Second Hospital of Shandong UniversityAdenomyosis, in Vitro Fertilization

Start: 2024-06-30End: 2030-01-01Updated: 2025-08-21

Related Papers

Effectiveness of Physiotherapy for Improving Functionality, Participation, and Quality of Life after a Stroke: Study Protocol for a Randomized Controlled Clinical Trial

Journal of Personalized Medicine2024-08-223 citations

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.

2011-04-1248 citations